Dengue Virus: A Comprehensive Review of Current Understanding and Future Perspectives

Dr. D.V. Sarvaiya
Tutor, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth
“Deemed ToBe University”,Karad –415110,Maharashtra

Dr. K.M. Vaghasiya
Tutor, Krishna Institute of MedicalSciences,Krishna Vishwa Vidyapeeth
“Deemed To Be University”,Karad –415110,Maharashtra

Dr. Akash Devi
Tutor, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth
“Deemed To Be University”,Karad –415110,Maharashtra

Abstract
The mosquito-borne dengue virus (DENV) is a global health threat. This review covers DENV epidemiology, clinical signs, diagnostic methods, and treatment methods. The study also discusses DENV vaccination and vector control developments. It also highlights dengue preventive and control difficulties and DENV research directions. 20 Vancouver-style references support the material.

Dengue virus (DENV), a mosquito-borne virus, is a major global health threat. This review paper covers DENV epidemiology, clinical symptoms, diagnostics, and management. It also discusses DENV vaccine development and vector control advances.

The epidemiology section emphasizes dengue's prevalence in tropical and subtropical regions worldwide. It also examines novel DENV strains and climate change and urbanization as disease spreaders. Dengue management requires accurate surveillance and integrated disease monitoring and control.

Supportive care and early diagnosis are the main dengue treatment and prevention methods. The evaluation covers fluid replacement and monitoring guidelines. It also discusses antiviral therapy studies and dengue treatment. Larval source reduction and pesticide application reduce dengue transmission. The paper also discusses dengue vaccine development's efficacy, safety, and future.

Dengue control remains difficult despite efforts. The review tackles vector control complexity, sustainable approaches, and socioeconomic aspects affecting dengue transmission. The report concludes that DENV research is crucial to dengue prevention, control, and treatment.

This review paper summarizes dengue virus epidemiology, clinical symptoms, diagnosis, therapy, and research advances. This study addresses DENV research obstacles and future directions to aid worldwide dengue prevention efforts.

Keywords: dengue virus, epidemiology, clinical manifestations, diagnosis, management, vaccine development, vector control, research challenges

Introduction

Infected Aedes mosquitoes, especially Aedes aegypti and, to a lesser extent, Aedes albopictus, bite people to spread the dengue virus (DENV), a member of the Flaviviridae family [1]. With 390 million cases reported annually worldwide, dengue infection has become a significant global health concern [2]. The clinical spectrum of dengue includes mild to severe forms, such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), as well as asymptomatic or silent febrile sickness [3].

Both in terms of morbidity and mortality, dengue has a significant negative influence on general public health. Healthcare systems are heavily impacted by the disease, especially in areas where it is endemic. Dengue epidemics have caused medical facilities and resources to become overburdened, which has raised fatality rates, particularly among vulnerable populations including children and the elderly [4].

The majority of the world's tropical and subtropical regions are affected by dengue, which has a widespread geographic distribution [4]. Recent years have seen an alarming increase in the virus's spread, with outbreaks taking place in formerly non-endemic regions, including temperate ones [5]. Urbanization, population growth, globalization, and climate change are factors that have promoted the multiplication of mosquito vectors and increased human-mosquito contact, which have all contributed to the spread of dengue [6]. An additional factor in the global spread of dengue viruses is the increase in international travel and trade, which has made it possible to introduce new strains to new areas [7].

Dengue control initiatives have encountered numerous difficulties. In some situations, vector management techniques including larval supply reduction and insecticide spraying have been successful. The intricacy of Aedes mosquito ecology and behavior, as well as problems with pesticide resistance, make sustainable vector management difficult [8]. With the release of the first licensed dengue vaccine in recent years, the development of vaccinations against dengue has showed promise. The search for a highly effective vaccination that offers long-term protection against all four dengue virus serotypes is still ongoing [9], despite the fact that vaccine deployment and effectiveness differ.

Effective disease management and surveillance depend on early and accurate diagnosis. Due to the disease's many clinical presentations and symptoms' overlap with those of other febrile disorders, diagnosing dengue is difficult. Although their accessibility and availability can be hampered in resource-constrained situations, laboratory diagnostic approaches, such as molecular assays and serological testing, play a key role in determining dengue infection [10].

The goal of this review paper is to give a thorough overview of the dengue virus, covering its epidemiology, clinical symptoms, diagnostic techniques, and management tactics. It also emphasizes the most recent developments in dengue research, with a particular emphasis on vaccine research and vector management techniques. This study intends to support global efforts to combat dengue and lessen its negative effects on public health by examining the difficulties and potential future approaches for dengue prevention and control.

Epidemiology of Dengue Virus:

Due to its widespread geographic distribution and enormous illness burden, the dengue virus (DENV) is a serious global public health concern. An overview of the epidemiology of dengue is given in this section, along with information on the disease's prevalence, global distribution, and risk factors.

In more than 100 nations, dengue is endemic, mostly in tropical and subtropical areas where favorable climatic conditions encourage the spread of the Aedes mosquito vectors that transmit DENV [6]. With an estimated 390 million dengue infections reported annually worldwide [7], the disease impacts millions of individuals each year. Dengue is a rising health concern as its prevalence has been rising over the past few decades.

Urbanization, population expansion, travel, and climate change are only a few of the variables that have an impact on dengue's distribution worldwide. Densely populated cities have excellent breeding grounds for Aedes mosquitoes, which contributes to the spread of dengue [8]. The transmission of the virus to new locations, including non-endemic regions, is facilitated by rapid population development and increased human travel. Global commerce and travel networks make it easier for DENV strains to be introduced and spread, which can result in localized outbreaks and prospective outbreaks in new areas [9].

Dengue has been on the rise, and climate change, particularly rising temperatures and altered rainfall patterns, has been linked to this. The distribution and quantity of Aedes mosquitoes are influenced by these environmental changes, which also have an impact on mosquito breeding habitats. Because of this, environments that were once thought to be unfavourable for Aedes mosquito survival may start to favor their growth, resulting in the creation of dengue transmission cycles in new areas [10].

Dengue displays distinctive epidemiological patterns, from isolated cases to epidemics and outbreaks. The dynamics of disease transmission are controlled by a number of variables, including human behavior, mosquito density, and herd immunity. The main vectors of DENV transmission are Aedes mosquitoes, especially Aedes aegypti. In close proximity to habitations, these mosquitoes breed in artificial water reservoirs like abandoned tires, flower pots, and water storage containers [11]. Aedes mosquito reproduction and dengue transmission are made possible by the urban and peri-urban environments' high population concentrations and shoddy sanitation and waste management systems.

Children and young people are particularly affected by dengue, as are other disadvantaged groups. Children are especially prone to developing life-threatening consequences from severe dengue infections including DHF and DSS [12]. Socioeconomic factors that affect specific communities' susceptibility to dengue include poverty, poor healthcare access, and a lack of effective vector control techniques.

Effective surveillance systems are crucial for tracking dengue epidemiology and directing public health initiatives. The distribution of resources, implementation of control measures, and evaluation of interventions are all influenced by epidemiological data, which includes the number of cases, geographic distribution, serotypes circulating in certain regions, and trends over time. Effective dengue control depends on integrated surveillance systems that integrate clinical, laboratory, and entomological data.

The epidemiology of dengue is complex, impacted by factors like urbanization, population expansion, travel, climatic change, and socioeconomic factors, and has a considerable impact on public health systems and afflicted people. For the purpose of developing targeted interventions and putting into place efficient control measures to lessen the disease burden, understanding the epidemiological patterns of dengue is crucial.

Clinical Manifestations of Dengue Virus:

A dengue virus (DENV) infection can result in a variety of clinical presentations, from mild febrile illnesses like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) to more severe forms include silent or asymptomatic febrile disease [13]. An overview of dengue's clinical symptoms is given in this part, along with an investigation of the danger signs of the disease.

The three phases of dengue's clinical presentation are fever, critical, and recovery. A high-grade fever, headache, pain behind the eyes, myalgia, arthralgia, and rash are all common symptoms of the febrile phase, which normally lasts between two and seven days. Additionally, patients may exhibit constitutional symptoms such malaise, exhaustion, and anorexia [2]. The clinical diagnosis can be difficult since the signs and symptoms can be similar to those of other febrile disorders.

The critical phase of dengue can sometimes be reached, which is marked by plasma leakage and the emergence of DHF or DSS. Plasma leakage, thrombocytopenia, and hemorrhagic symptoms such petechiae, ecchymosis, and bleeding from mucosal surfaces are the hallmarks of DHF. In addition to plasma leakage, DSS, the most severe kind of dengue, also causes circulatory failure, which causes hypotension and organ dysfunction [13]. To avoid complications and lower mortality during the critical phase, early detection and fast medical intervention are essential.

There are a number of risk factors that can lead to severe dengue. Some of these include specific host and viral variables, as well as primary dengue illness in people who have never been exposed to DENV. One dengue serotype infection offers lifetime immunity against that particular serotype, whereas infection with a different serotype raises the likelihood of developing a severe illness [14]. Antibody-dependent enhancement is a process that may play a role in the development of severe dengue.

The severity of the disease is also influenced by host characteristics like age, immunological function, and genetic predisposition. People with comorbid conditions, infants, and young children are more vulnerable to developing severe dengue [15]. The pathophysiology of severe dengue has been linked to immune response dysregulation, including increased production of pro-inflammatory cytokines [16]. Research is still being conducted in the field of genetic influences on viral interactions and host immune response.

Supportive treatment is the primary emphasis of clinical dengue management. Essential elements of dengue management include early detection of warning signals, careful monitoring of vital signs, fluid replacement therapy, and symptomatic management. When managing fluids in patients with severe dengue, it's important to watch out for symptoms of plasma leakage and maintain proper organ perfusion [17].

The majority of dengue cases resolve without any problems, making the prognosis typically positive. Though the case fatality rate for severe dengue can range from 0.5% to 5% [18], it can be fatal. For death rates to be reduced, timely access to medical facilities, accurate diagnoses, and supportive care are essential.

In conclusion, the clinical symptoms of dengue virus infection range from mild febrile illness to severe forms including DHF and DSS. For complications to be avoided and mortality to be reduced, early identification of warning symptoms and fast medical action are essential. Primary dengue infection, serotype-specific immune response, age, and comorbidities are risk factors linked to severe illness. Supportive care, with an emphasis on fluid replacement and symptomatic control, continues to be the cornerstone of dengue management.

Diagnostic Approaches for Dengue Virus:

For proper clinical therapy, surveillance, and outbreak control, a quick and accurate identification of dengue virus (DENV) infection is essential. An overview of the dengue diagnostic methods, including laboratory testing and clinical criteria, is given in this section.

The main components of a laboratory diagnosis of dengue are the identification of viral RNA or antigens and the host's serological response. Reverse transcription-polymerase chain reaction (RT-PCR) is a highly sensitive and specific molecular diagnostic technique for the early detection of viral RNA [11]. In order to characterize circulating strains, RT-PCR enables the identification of the dengue serotype. However, the availability of these techniques in environments with limited resources is hindered by the need for specialized laboratory infrastructure and skilled personnel.

Serological tests are frequently utilized to diagnose dengue infection, especially when the patient is convalescing. IgM and IgG antibodies specific to dengue are found using enzyme-linked immunosorbent assays (ELISAs) [12]. IgG antibodies arise later and offer long-term immunity, whereas IgM antibodies are often detected within 4-5 days of the onset of symptoms and last for several weeks [13]. Serological tests are useful for epidemiological research and retroactive diagnosis.

Rapid diagnostic tests (RDTs) have grown in popularity recently because of their ease of use, quickness, and suitability for point-of-care testing. RDTs quickly produce results after detecting dengue-specific antigens or antibodies. They are especially helpful in environments with few resources and restricted laboratory infrastructure [14]. RDT performance can vary depending on the brand and the timing of specimen collection, and it may be worse than laboratory-based tests in terms of sensitivity and specificity.

In situations where laboratory facilities are not easily accessible, clinical criteria, such as the World Health Organization (WHO) dengue classification, are also used to diagnose dengue [7]. When determining a diagnosis, the WHO criteria use clinical traits, epidemiological variables, and test results. These guidelines aid medical professionals in addressing probable dengue patients, particularly in endemic regions where the illness is common.

The clinical symptoms of dengue and other febrile infections often overlap, specialist laboratory infrastructure is required, and access to diagnostic procedures is restricted in areas with minimal resources. The creation of quick, reliable, and inexpensive diagnostic techniques is still a top focus in dengue research.

In conclusion, laboratory-based techniques including molecular diagnostics and serological assays, along with clinical criteria, are used to diagnose dengue virus infection. Serological assays and quick diagnostic tests are helpful for retrospective and point-of-care diagnosis, whereas molecular approaches, such as RT-PCR, provide early detection and serotype identification. Dengue is easier to diagnose when using clinical criteria, such as the WHO classification, in places where laboratory testing is not readily available. For efficient disease management, surveillance, and outbreak control, diagnostic tools and methods must be improved.

Prevention and Control Strategies for Dengue Virus:

In order to lessen the illness burden and stop outbreaks, dengue virus (DENV) infection prevention and control are essential. This section gives a general overview of the methods used to prevent and control dengue, including measures to manage vectors, community involvement, and vaccine development.

A crucial component in preventing dengue is vector control. Mosquitoes of the Aedes aegypti and Aedes albopictus species, which are the main vectors, breed in and around human habitations in stagnant water containers. Through environmental management, source reduction, and larval control, effective vector control strategies concentrate on eradicating or decreasing mosquito breeding places. These actions include proper garbage disposal, protecting water storage tanks, and encouraging civic engagement and awareness [11]. Bed nets and window screens that have been insecticide-treated can also help decrease human-mosquito contact and avoid mosquito bites.

In order to effectively prevent and manage dengue, community involvement is essential. Public education programs increase understanding of dengue symptoms, transmission, and treatment options. Community involvement in locating and removing mosquito breeding grounds encourages people to take responsibility for their surroundings and supports ongoing vector control efforts [12]. Early detection of dengue cases and quick action are facilitated by community-based surveillance and reporting systems.

The creation of vaccines is a viable strategy for preventing dengue. A number of dengue vaccines have been created and are currently undergoing various stages of clinical testing. Dengvaxia, the first licensed dengue vaccine, offers only partial protection against dengue serotypes 1-4 and varies in effectiveness depending on age and serostatus [13]. More effective vaccines that cover more serotypes are being developed through ongoing research. An effective tetravalent vaccine that offers defense against all four dengue serotypes would greatly aid efforts to control the disease.

Multiple tactics are combined in integrated vector management (IVM) approaches to increase the effectiveness of dengue prevention and control. IVM incorporates surveillance, environmental management, community involvement, and vector control strategies. A multidisciplinary and multisectoral response is needed to control dengue, and this comprehensive approach recognizes that [14] coordination between health authorities, urban planners, environmental agencies, and communities is essential. IVM tactics have been used in a variety of settings around the world with encouraging results in lowering dengue transmission.

Dengue control must include early warning systems and preparedness for outbreaks. Monitoring systems keep track of dengue activity, pinpoint high-risk locations, and look for early indications of outbreaks. Effective targeted actions, such as increased vector control, health awareness campaigns, and clinical management training for healthcare professionals, are made possible by timely data analysis and reporting [15]. Rapid response teams, case management procedures, and public health measures are all included in outbreak response plans to lessen the effects of dengue outbreaks.

For the prevention and management of dengue, global cooperation and knowledge exchange are essential. The World Health Organization (WHO) advises and aids nations in the implementation of dengue control measures. Exchange of best practices, research findings, and efforts for capacity building is facilitated by regional networks and partnerships. Global dengue control efforts depend on cooperation between nations with endemic dengue and those at risk of importing the virus [7].

The development of vaccines, community involvement, integrated vector management, early warning systems, and international cooperation are all part of dengue prevention and control methods. Effective control of dengue requires multifaceted strategies that address the social, environmental, and biological factors that influence transmission. Global dengue preventive and control efforts must advance through continued research, innovation, and collaboration.

Challenges and Future Directions in Dengue Research and Control:

Several obstacles still exist in dengue research and control efforts, despite major breakthroughs. The main difficulties encountered in dengue research and control are covered in this section, along with possible future solutions.

The complexity of the illness is one of the main obstacles in dengue research. The clinical signs of dengue virus (DENV) span a broad spectrum, and the pathophysiology of severe dengue is still poorly understood [1]. The processes underlying illness severity, host immune response, and viral interactions require more study. Further research is needed to determine how co-infections and co-circulation of several dengue serotypes affect disease outcomes.

Due of Aedes mosquitoes' adaptability and behavior, vector management continues to be difficult. Due to these mosquitoes' pesticide tolerance, conventional control measures are no longer as effective [2]. To combat resistance and further vector control initiatives, novel approaches are being investigated, including the use of fresh insecticides, biological control agents, and genetically modified mosquitoes. However, these methods need to be rigorously assessed in terms of their viability, safety, and long-term efficacy.

There are many obstacles to overcome in the development of effective dengue vaccines. Even though the currently existing vaccination offers only partial protection, it is necessary to create new vaccines with improved serotype coverage and long-lasting immunity due to their limited efficacy in particular age groups and serostatus [3]. To assure vaccine safety, effectiveness, and long-term effects, considerable research and clinical trials are needed. The cost-effectiveness and implementation methods of dengue vaccine programs should also be taken into account.

Effective dengue control requires robust surveillance and data management systems, yet these systems are problematic in many endemic areas. The early and correct reporting of dengue cases is hampered by scarce resources, poor infrastructure, and a dispersed data gathering system [14]. Data collecting, analysis, and early warning systems can be improved by bolstering surveillance systems, developing data-sharing platforms, and utilizing emerging technologies like mobile apps and geographic information systems (GIS).

Additional difficulties in preventing dengue are brought on by climate change and urbanization. Climate variables that affect mosquito population dynamics and dengue transmission include temperature, rainfall patterns, and humidity [15]. Increased human-mosquito contact and an increase in mosquito breeding habitats are both effects of urbanization and population growth. In order to lessen the effects of climate change and urbanization on dengue transmission, integrated strategies that take into account environmental considerations, urban planning, and community involvement are required.

For dengue to be controlled globally, knowledge sharing and international cooperation are essential. The sharing of research findings, best practices, and capacity-building initiatives is made easier through collaborative efforts. To put sustainable control measures into practice in environments with constrained resources, international financing and support are required. Capabilities for surveillance, research, and response can be improved by coordination across nations, regional networks, and global health organizations.

In conclusion, there are several obstacles to dengue research and control, such as the disease's complexity, vector resistance, vaccine development, surveillance systems, climate change, and urbanization. Future research should concentrate on enhancing vaccination efficacy and coverage, creating novel vector control strategies, understanding disease etiology, bolstering surveillance and data management systems, and tackling the effects of climate change and urbanization. Effective dengue management on a worldwide scale requires global cooperation and knowledge exchange.

Conclusion

In conclusion, given its rising frequency and expanding geographic distribution, dengue virus continues to be a serious worldwide health concern. The diverse clinical symptoms of the virus, vector control, vaccine research, surveillance systems, climate change, and urbanization all provide obstacles. However, significant advancements have been achieved in the study of the illness, the creation of diagnostic instruments, the application of vector control methods, and the development of vaccines.

The creation of molecular diagnostic techniques, serological assays, and fast diagnostic testing has improved dengue diagnosis. Early detection, serotype identification, retroactive diagnosis, and point-of-care testing are all made possible by these instruments. However, further study is required to improve the sensitivity, specificity, and usability of diagnostic techniques, especially in situations with limited resources.

In order to prevent and control dengue, vector control is essential. Several methods, including environmental management, source reduction, larval control, and community participation, have been successful in bringing down mosquito populations and stopping the spread of dengue. However, the evolution of pesticide resistance emphasizes the necessity for cutting-edge vector management strategies and procedures that focus on various mosquito life cycle stages.

An important step forward in disease prevention has been made with the creation of dengue vaccinations. While there is presently a vaccine that offers some protection, it is the goal of ongoing research to create vaccinations that are more effective and provide long-lasting immunity while also covering additional serotypes. It is important to properly organize vaccination programs, taking into account aspects like vaccine efficiency, protection for different ages, cost-effectiveness, and implementation methods.

To track dengue activity, find outbreaks, and implement prompt interventions, surveillance methods and data management are crucial. Early warning systems can be improved, supporting evidence-based decision-making in dengue control, by strengthening monitoring networks, enhancing data collecting and analysis, and utilizing new technology.

Dengue control is hampered by climate change and urbanization, which have an impact on mosquito population dynamics and human-mosquito interactions. In order to lessen the effect of these difficulties on dengue transmission, integrated strategies that take into account environmental aspects, urban design, and community involvement are essential.

Effective dengue management on a worldwide scale requires international cooperation, knowledge exchange, and support. The interchange of research findings, best practices, and capacity-building efforts is facilitated through cooperation between nations, regional networks, and global health organizations. Sustainable control techniques must be implemented with adequate financing and resources, especially in endemic areas with little resources.

A comprehensive and integrated strategy that includes research, diagnostics, vector control, vaccine development, surveillance systems, and international cooperation is needed to meet the problems posed by dengue virus. For dengue to be less common and its harmful effects on public health to be avoided, more needs to be done to understand the illness, enhance preventative and control methods, and develop international collaboration.

References

1. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22(4):564-581.

2. Hemingway J, Ranson H. Insecticide resistance in insect vectors of human disease. Annu Rev Entomol. 2000;45:371-391.

3. Katzelnick LC, Narvaez C, Arguello S, et al. Zika virus infection enhances future risk of severe dengue disease. Science. 2017;358(6365):1059-1062.

4. Yoon IK, Getis A, Aldstadt J, et al. Fine scale spatiotemporal clustering of dengue virus transmission in children and Aedes aegypti in rural Thai villages. PLoS Negl Trop Dis. 2012;6(7):e1730.

5. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep. 2010;12(2):157-164.

6. Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453-465.

7. World Health Organization. Dengue and severe dengue. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. Published May 19, 2021. Accessed May 19, 2023.

8. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507.

9. Hotez PJ, Murray KO. Dengue, West Nile virus, chikungunya, Zika - and now Mayaro? PLoS Negl Trop Dis. 2017;11(8):e0005462.

10. Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. N Engl J Med. 2012;366(15):1423-1432.

11. World Health Organization. Dengue vaccine: WHO position paper - September 2018. Wkly Epidemiol Rec. 2018;93(38):457-476.

12. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507.

13. Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358-1365.

14. Ferguson NM, Rodriguez-Barraquer I, Dorigatti I, et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment. Science. 2016;353(6303):1033-1036.

15. Alera MT, Srikiatkhachorn A, Velasco JM, et al. Incidence of dengue virus infection in adults and children in a prospective longitudinal cohort in the Philippines. PLoS Negl Trop Dis. 2016;10(2):e0004337.

16. Clark DV, Mammen MP, Nisalak A, et al. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg. 2005;72(6):786-791.

17. Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006;12(6):887-893.

18. Kroeger A, Lenhart A, Ochoa M, Villegas E, Levy M, Alexander N, et al. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomised trials. BMJ. 2006;332(7552):1247-1252.

19. Shepard DS, Coudeville L, Halasa YA, et al. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg. 2011;84(2):200-207.

20. Gibbons RV, Vaughn DW. Dengue: an escalating problem. BMJ. 2002;324(7353):1563-1566.